| Title |
Second-line treatment of small-cell lung cancer
|
|---|---|
| Published in |
Current Oncology Reports, August 2006
|
| DOI | 10.1007/s11912-006-0030-8 |
| Pubmed ID | |
| Authors |
Cecilia MacCallum, Heidi H. Gillenwater |
| Abstract |
Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population. The only second-line treatment for small-cell lung cancer approved by the US Food and Drug Administration is topotecan. Other agents have been investigated and have shown modest efficacy. These include vinorelbine, irinotecan, etoposide, paclitaxel, and gemcitabine. Novel "targeted therapies" have shown disappointing results in this disease. Much of the recent work has focused on investigating alternative dosing and scheduling of topotecan. Combination therapies have also been investigated, and some have been shown to increase activity over single agents, but toxicity and quality of life variables are imperative in the treatment of this patient population. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 21% |
| Student > Ph. D. Student | 4 | 21% |
| Student > Master | 3 | 16% |
| Other | 2 | 11% |
| Researcher | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 2 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 21% |
| Biochemistry, Genetics and Molecular Biology | 3 | 16% |
| Engineering | 2 | 11% |
| Chemistry | 2 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 4 | 21% |
| Unknown | 3 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2016.
All research outputs
#7,451,284
of 22,780,165 outputs
Outputs from Current Oncology Reports
#300
of 876 outputs
Outputs of similar age
#22,748
of 65,406 outputs
Outputs of similar age from Current Oncology Reports
#2
of 2 outputs
Altmetric has tracked 22,780,165 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 876 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 65,406 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.